# DESCRIPTION

## BACKGROUND

- motivate pRNA 3WJ motifs

## DETAILED DESCRIPTION

- introduce RNA nanomotifs
- describe limitations of pRNA 3WJs
- disclose novel trifurcate pRNA 3WJ motifs
- describe thermodynamic parameters of pRNA 3WJs
- show increased stability of certain 3WJs
- describe effect of metal ions on pRNA 3WJs
- provide disclaimer on scope of disclosure
- define terms used in specification
- describe use of "a" and "an"
- define "or combinations thereof"
- describe use of "about" and "approximately"
- define "substantially"
- describe use of "one embodiment"
- define "pharmaceutically acceptable"
- define "biologically active"
- define "pure" and "substantially pure"
- describe non-limiting examples of animals
- define "treatment" and "prevention"
- define "therapeutic composition" and "pharmaceutical composition"
- define "effective amount"
- define "ameliorate"
- describe three-way junction (3WJ) scaffold
- describe biophysical studies on pRNA 3WJ deletion mutant constructs
- describe functional RNAs designed using enhanced stability phi29 pRNA 3WJ deletion mutants

### Experimental

- design pRNA 3WJ constructs
- describe UV optical melting method
- perform UV optical melting experiments
- predict pRNA 3WJ secondary structure and free energy
- describe electrophoretic gel mobility shift assays
- perform electrophoretic gel mobility shift assays
- report pRNA 3WJ nanomotif stabilities
- analyze melt curves and thermodynamic parameters
- investigate metal ion binding effects
- analyze electrophoretic gel mobility shift assay results
- discuss 3WJ stabilities in relation to loop-loop interaction stabilities and self-assembly
- introduce pRNA 3WJ constructs
- analyze thermodynamic stability
- discuss structure-energetics relationships
- evaluate free energy predictions
- describe serum stability experiments
- analyze serum stability results
- discuss melting temperatures
- introduce examples of pRNA oligonucleotides
- describe RNA junction scaffold embodiments
- specify 3WJb sequence features
- specify 3WJa sequence features
- specify 3WJc sequence features
- provide additional RNA junction scaffold embodiments
- describe RNA junction scaffold
- specify 3WJa sequence
- specify 3WJb sequence
- specify 3WJc sequence
- describe phi29 pRNA 3WJ construct
- describe M2 3WJ construct
- describe SF5 3WJ construct
- describe GA1 3WJ construct
- provide non-limiting examples of phi29 pRNA three-sequence sets
- provide non-limiting examples of M2 pRNA three-sequence sets
- provide non-limiting examples of SF5 pRNA three-sequence sets
- provide non-limiting example of GA1 pRNA three-sequence set
- describe generic representations of pRNA three-sequence sets
- describe use of pRNA 3WJ constructs as scaffolds for biologically active moieties
- claim RNA junction scaffold with specific sequences and structure
- define RNA junction scaffold
- specify absence of unpaired nucleotides
- describe three-way junction domain
- specify absence of unpaired nucleotides in 3WJa sequence
- specify absence of unpaired nucleotides in 3WJb sequence
- describe RNA junction scaffold with specific sequences
- specify absence of unpaired nucleotides in specific positions
- describe conjugate comprising RNA 3WJ scaffold
- describe composition with conjugate and pharmaceutically-acceptable vehicle
- specify length of 3WJa, 3WJb, and 3WJc sequences
- provide general statement on scope of disclosure

